CA9 and glioblastoma: Furthermore, the DATE possessed potent antitumor activity in multiple patient-derived solid tumor models of GBM and ccRCC containing both robust constitutive CA9 expression in response to VHL loss as well as in models with microenvironmentally-driven CA9 upregulation.